Clinical trials: Glaucoma, Open-Angle Glaucoma Eye
Primary Open-Angle Glaucoma
GlaucoT Glaucoma Treatment Glasses in the Treatment of Primary Open-Angle Glaucoma
Glaucoma is a chronic and progressive optic neuropathy characterized by degeneration of ganglion cells and axons with loss of visual function.
- Trial name
- GlaucoT (NCT05253534)
- Testing
- GlaucoT Glaucoma Treatment Device
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Glaucot Teknoloji Anonim Sirketi
Open-angle Glaucoma, Ocular Hypertension
Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32
The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after six weeks of treatment in Caucasian and Japanese subjects.
- Trial name
- NCT00047606
- Testing
- IOP Lowering Medications
- Volunteers
- 84 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy
Primary open angle glaucoma (POAG) is associated with inadequate drainage of the aqueous humor via the trabecular meshwork through the Schlemm's canal towards the systemic circulation.
- Trial name
- NCT01766947
- Testing
- Sensimed Triggerfish
- Where
- France
- Sponsor
- Sensimed AG
Ocular Hypertension, Primary Open Angle Glaucoma
Glaucoma Adherence Study
The purpose of this study is evaluate adherence to DuoTrav® when reinforced by the use of the Travalert™ Dosing Aid.
- Trial name
- GAS (NCT00676637)
- Testing
- Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav), Travalert Dosing Aid
- Where
- 4 sites in France, Italy and 2 more
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-004.
- Trial name
- OLE2 (NCT02537015)
- Testing
- Bimatoprost
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- ForSight Vision5, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.
- Trial name
- NCT04830397
- Testing
- QLS-101, Timolol Maleate
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Qlaris Bio, Inc.
Primary Open Angle Glaucoma
Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma
A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to…
- Trial name
- CATALYST (NCT05564091)
- Testing
- Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery
- Where
- 4 sites in United States, Germany
- Volunteers
- 78 people
- Sponsor
- Nova Eye, Inc.
Open Angle Glaucoma, Ocular Hypertension
Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure
The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with travoprost 0.004% / timolol 0.5% compared to beta-blocker monotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02003391
- Testing
- Beta-blocker monotherapy, Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
- Volunteers
- 157 people
- Sponsor
- Alcon Research
Open Angle Glaucoma
STAR-LIFE: a Post-market Registry on MINIject
As part of the post-market clinical follow-up (PMCF), this registry is developed to ensure real-world data collection on MINIject device.
- Trial name
- STAR-LIFE (NCT05269680)
- Testing
- Implant Miniject
- Where
- 15 sites in Austria, Germany and 2 more
- Volunteers
- 320 people
- Sponsor
- iSTAR Medical
Open-angle Glaucoma
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost
Evaluation of the intraocular pressure (IOP) lowering effect of two iStent inject devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to…
- Trial name
- NCT01444040
- Testing
- iStent inject, Travoprost
- Where
- Armenia
- Volunteers
- 196 people
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma
Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery vs.
- Trial name
- NCT01841450
- Testing
- iStent, Cataract surgery
- Where
- 14 sites in United States
- Volunteers
- 360 people
- Sponsor
- Glaukos Corporation
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00868894
- Testing
- DE-104 medium concentration, DE-104 high concentration, 0.005% latanoprost
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Santen Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).
- Trial name
- NCT01594970
- Testing
- Bimatoprost 0.01%
- Where
- South Korea
- Volunteers
- 800 people
- Sponsor
- Allergan
Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension
The goal of this clinical study is to learn how effective and safe is a single administration of PA5346 Ocular Implant for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT06964061
- Testing
- PA5436 Ocular Implant, 115mcg
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- PolyActiva Pty Ltd
Subjects With Primary Open-angle Glaucoma (POAG)
Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of two iStent devices in eyes of subjects with primary open-angle glaucoma
- Trial name
- NCT01252862
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Graft vs Host Disease, Congenital Aniridia
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely.
- Conditions
- Graft vs Host Disease, Congenital Aniridia, Chemical Burns, Stevens-Johnson Syndrome
- Trial name
- NCT02945176
- Testing
- ARGOS-IO system
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Primary Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
To evaluate the safety and efficacy of PF-04217329.
- Trial name
- NCT00572455
- Testing
- PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose
- Where
- 23 sites in United States
- Volunteers
- 318 people
- Sponsor
- Pfizer
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study and will evaluate IOP reduction in newly diagnosed patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians…
- Trial name
- NCT01628614
- Testing
- Standard of Care
- Where
- Spain
- Volunteers
- 4,812 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH
This study is a double-masked, randomized, parallel group study in patients with open angle glaucoma or ocular hypertension. The aim of this study is to verify the efficacy of the fixed combination of Latanoprost 50 mcg / mL /…
- Trial name
- NCT01721707
- Testing
- Latanoprost+Brinzolamide combination, Latanoprost
- Where
- Brazil
- Sponsor
- Adapt Produtos Oftalmológicos Ltda.
Open Angle Glaucoma
STAR-LIFE Registry: STARflo Glaucoma Implant Clinical Experience Program
STARflo is a novel suprachoroidal Glaucoma Drainage Device (GDD), bleb-free, exhibiting anti-fibrotic properties. Release of this CE Marked implant has been limited to leading Glaucoma Centers in Europe.
- Trial name
- NCT02825264
- Testing
- STARflo Implant
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 70 people
- Sponsor
- iSTAR Medical